You have free access to this content

Cancer

Cover image for Vol. 117 Issue 16

15 August 2011

Volume 117, Issue 16

Pages 3627–3867

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Erratum
    1. You have free access to this content
    2. You have free access to this content
  2. Review Articles

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Erratum
    1. You have free access to this content
      Gastrointestinal cancer and brain metastasis : A rare and ominous sign (pages 3630–3640)

      Pauline H. Go, Zachary Klaassen, Michael C. Meadows and Ronald S. Chamberlain

      Article first published online: 11 FEB 2011 | DOI: 10.1002/cncr.25940

      Brain metastases from gastrointestinal cancers occur in <4% of patients and represent an advanced stage of disease. Although the prognosis is poor, prolonged survival and improvement in clinical symptoms has been shown to be best achieved with surgical resection and whole brain radiation therapy.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Erratum
    1. Disease Site

      Breast Disease
      You have free access to this content
      Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer : A Surveillance, Epidemiology, and End Results-Medicare Study (pages 3641–3649)

      Mariana Chavez-MacGregor, Hui Zhao, Shenying Fang, Tomasz P. Srokowski, Gabriel N. Hortobagyi and Sharon H. Giordano

      Article first published online: 24 FEB 2011 | DOI: 10.1002/cncr.25972

      In this large, retrospective, cohort study, the authors evaluated the patterns of use and the risk of thromboembolic events associated with erythropoietin-stimulating agents (ESAs) in older patients with breast cancer. The use of ESAs significantly increased the risk of thromboembolic events, and the development of these complications was dose-dependent.

    2. You have free access to this content
      Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone (pages 3650–3657)

      Phoebe Holmes, Joshua Lloyd, Inna Chervoneva, Edward Pequinot, Dennis B. Cornfield, Gordon F. Schwartz, Kathleen G. Allen and Juan P. Palazzo

      Article first published online: 11 FEB 2011 | DOI: 10.1002/cncr.25942

      We conducted a single-institution analysis of several cases of breast ductal carcinoma in situ (DCIS) in which patients were treated with breast conservation surgery alone and followed up for as many as 24 years. Morphological features and prognostic markers were analyzed to determine their significance for predicting time to recurrence of DCIS.

    3. You have free access to this content
      Triple-negative breast cancer in Hispanic patients : High prevalence, poor prognosis, and association with menopausal status, body mass index, and parity (pages 3658–3669)

      Fernando Lara-Medina, Víctor Pérez-Sánchez, David Saavedra-Pérez, Monika Blake-Cerda, Claudia Arce, Daniel Motola-Kuba, Cynthia Villarreal-Garza, Ana Maria González-Angulo, Enrique Bargalló, Jose Luis Aguilar, Alejandro Mohar and Óscar Arrieta

      Article first published online: 8 MAR 2011 | DOI: 10.1002/cncr.25961

      The prevalence of triple-negative breast cancer in a Hispanic study population was greater than that reported in white women with breast cancer. Triple-negative breast cancer was associated with a poor prognosis, a high risk of locoregional recurrence, and poor disease-free and cancer-specific survival.

    4. You have free access to this content
      Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer (pages 3670–3681)

      Anika Nagelkerke, Hilda Mujcic, Johan Bussink, Bradly G. Wouters, Hanneke W. M. van Laarhoven, Fred C. G. J. Sweep and Paul N. Span

      Article first published online: 11 FEB 2011 | DOI: 10.1002/cncr.25938

      LAMP3 was found to be associated with hypoxia in breast cancer cell lines, xenografts, and tissues. In a cohort of breast cancer patients, LAMP3 mRNA and protein had independent prognostic value.

    5. You have free access to this content
      Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers (pages 3682–3690)

      Yasuto Naoi, Kazuki Kishi, Tomonori Tanei, Ryo Tsunashima, Naoomi Tominaga, Yosuke Baba, Seung Jin Kim, Tetsuya Taguchi, Yasuhiro Tamaki and Shinzaburo Noguchi

      Article first published online: 8 FEB 2011 | DOI: 10.1002/cncr.25953

      Sequential administration of combined paclitaxel plus combined 5-fluorouracil, epirubicin, and cyclophosphamide is one of the most common neoadjuvant chemotherapy regimens for patients with primary breast cancer. Because a predictor of pathologic complete response to this regimen had not been developed, the authors developed such a predictor by using a DNA microarray for gene expression analysis of breast tumor tissues.

    6. Gastrointestinal Disease
      You have free access to this content
      Dysfunctional transforming growth factor-β signaling with constitutively active notch signaling in Barrett's esophageal adenocarcinoma (pages 3691–3702)

      Jonathan Mendelson, Shumei Song, Ying Li, Dipen M. Maru, Bibhuti Mishra, Marta Davila, Wayne L. Hofstetter and Lopa Mishra

      Article first published online: 8 FEB 2011 | DOI: 10.1002/cncr.25861

      This study demonstrates that loss of TGF-β signaling member β2SP with constitutively active Notch signaling in Barrett's esophageal adenocarcinoma. These studies could lead to further insight into molecular events involved in dysfunctional progenitor cells in esophageal adenocarcinoma.

    7. You have free access to this content
      Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer (pages 3703–3712)

      Jin-hong Park, Sang Min Yoon, Chang Sik Yu, Jong Hoon Kim, Tae Won Kim and Jin Cheon Kim

      Article first published online: 15 FEB 2011 | DOI: 10.1002/cncr.25943

      This study including 240 locally advanced rectal cancer patients compared preoperative chemoradiotherapy (CRT) with postoperative CRT using oral capecitabine. There was no difference in local control, survival, toxicities, and surgical complications between the two arms, but patients with low-lying rectal tumors who were given preoperative CRT had an increased rate of sphincter preservation.

    8. You have free access to this content
      Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma (pages 3713–3722)

      Chiaojung Jillian Tsai, Christopher H. Crane, John M. Skibber, Miguel A. Rodriguez-Bigas, George J. Chang, Barry W. Feig, Cathy Eng, Sunil Krishnan, Dipen M. Maru and Prajnan Das

      Article first published online: 15 FEB 2011 | DOI: 10.1002/cncr.25973

      The authors evaluated the prognostic impact of the number of lymph nodes examined among 372 patients with rectal cancer who had pathologically negative lymph nodes after receiving preoperative chemoradiation. The number of lymph nodes examined was associated independently with disease relapse and cancer-specific survival.

    9. Genitourinary Disease
      You have free access to this content
      Conditional survival predictions after surgery for patients with penile carcinoma (pages 3723–3730)

      Rodolphe Thuret, Maxine Sun, Firas Abdollah, Jan Schmitges, Shahrokh F. Shariat, François Iborra, Jacques Guiter, Jean-Jacques Patard, Paul Perrotte and Pierre I. Karakiewicz

      Article first published online: 24 FEB 2011 | DOI: 10.1002/cncr.25974

      The authors developed and externally validated the first conditional nomogram for predicting squamous cell carcinoma of the penis cancer-specific mortality-free survival that allows consideration of the length of survivorship.

    10. Gynecologic Oncology
      You have free access to this content
      Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer : Results of a Phase 2 Study (pages 3731–3740)

      Kathryn F. McGonigle, Howard G. Muntz, Jacqueline Vuky, Pamela J. Paley, Dan S. Veljovich, Benjamin E. Greer, Barbara A. Goff, Heidi J. Gray and Thomas W. Malpass

      Article first published online: 24 FEB 2011 | DOI: 10.1002/cncr.25967

      A weekly topotecan and biweekly bevacizumab combination demonstrates acceptable toxicity and very good efficacy in patients with platinum-resistant ovarian cancer. Patients treated with 2 prior regimens received greater benefit than patients treated with 1.

    11. You have free access to this content
      Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma (pages 3741–3749)

      Matthew P. Schlumbrecht, Charlotte C. Sun, Karen N. Wong, Russell R. Broaddus, David M. Gershenson and Diane C. Bodurka

      Article first published online: 11 FEB 2011 | DOI: 10.1002/cncr.25929

      Smoking adversely affects both overall survival and progression-free survival in patients with low-grade serous ovarian carcinoma. However, the current study indicates that hormone consolidation therapy may be protective in this group of women.

    12. Head and Neck Disease
      You have free access to this content
      Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy (pages 3750–3757)

      Xin An, Feng-Hua Wang, Pei-Rong Ding, Ling Deng, Wen-Qi Jiang, Li Zhang, Jian-Yong Shao and Yu-Hong Li

      Article first published online: 11 FEB 2011 | DOI: 10.1002/cncr.25932

      Plasma Epstein-Barr virus (EBV) DNA is of predictive value for prognosis in metastatic/recurrent nasopharyngeal carcinoma in patients undergoing palliative chemotherapy. The pre-treatment plasma EBV DNA level as well as the early decrease of plasma EBV DNA after chemotherapy enable easy and early discrimination between patients who will and those who will not benefit from continued treatment.

    13. Hematologic Malignancies
      You have free access to this content
      Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression (pages 3758–3762)

      Jatin Shah, Joan Bladé, Pieter Sonneveld, Jean-Luc Harousseau, Keith Lantz, Anil Londhe, Colin Lowery and Robert Z. Orlowski

      Article first published online: 15 FEB 2011 | DOI: 10.1002/cncr.25937

      A rapid and early monoclonal (M) protein response during initial therapy in patients with multiple myeloma had been identified as a predictor of superior long-term outcome in some—but not all—studies. This study revealed that a robust early M protein response was a good prognostic factor for long-term outcome of myeloma patients with relapsed and/or refractory disease receiving bortezomib or PLD + bortezomib.

    14. Lung Disease
      You have free access to this content
      Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma (pages 3763–3773)

      Dan Liu, Yi Huang, Bojiang Chen, Jing Zeng, Na Guo, Shangfu Zhang, Lunxu Liu, Hong Xu, Xianming Mo and Weimin Li

      Article first published online: 8 MAR 2011 | DOI: 10.1002/cncr.25959

      This study provided the first clinical evidence that activated components of mammalian target of rapamycin pathway, not total protein, are predictors of poor prognosis in nonsmall cell lung carcinoma (NSCLC). Moreover, evaluating protein-expression profiles of these molecules might be a new strategy for individual therapy in subjects with NSCLC.

    15. You have free access to this content
      Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer (pages 3774–3780)

      Rachel A. Murphy, Marina Mourtzakis, Quincy S. C. Chu, Vickie E. Baracos, Tony Reiman and Vera C. Mazurak

      Article first published online: 15 FEB 2011 | DOI: 10.1002/cncr.25933

      Compared with standard of care, supplementation with fish oil resulted in a 2-fold increase in chemotherapy efficacy and a trend toward increased survival in patients with advanced lung cancer.

    16. You have free access to this content
      Local progression after radiofrequency ablation for pulmonary metastases (pages 3781–3787)

      Erik M. von Meyenfeldt, Warner Prevoo, David Peyrot, Nathalie Lai A Fat, Sjaak J. A. Burgers, Michel W. Wouters and Houke M. Klomp

      Article first published online: 11 FEB 2011 | DOI: 10.1002/cncr.25958

      Radiofrequency ablation (RFA) for pulmonary (oligo)metastatic disease is associated with a considerable rate of local progression (>30%). Nevertheless, long-term survival rates are still acceptable after repeated RFA.

    17. Neuro-Oncology
      You have free access to this content
      Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors : A prospective, randomized, placebo-controlled, double-blind pilot trial (pages 3788–3795)

      Simon Kirste, Markus Treier, Sabine Jolie Wehrle, Gerhild Becker, Mona Abdel-Tawab, Kathleen Gerbeth, Martin Johannes Hug, Beate Lubrich, Anca-Ligia Grosu and Felix Momm

      Article first published online: 1 FEB 2011 | DOI: 10.1002/cncr.25945

      This prospective, randomized, placebo-controlled, double-blind pilot trial in 40 patients receiving radiation therapy for brain tumors showed that Boswelliaserrata significantly reduced cerebral edema compared with placebo.

    18. Discipline

      Disparities Research
      You have free access to this content
      Cancer survivorship and sexual orientation (pages 3796–3804)

      Ulrike Boehmer, Xiaopeng Miao and Al Ozonoff

      Article first published online: 9 MAY 2011 | DOI: 10.1002/cncr.25950

      In the absence of cancer surveillance by sexual orientation in registries, these findings show how cancer impacts sexual minorities differently by sex. These novel findings with respect to sexual orientation can be used to set priorities for lesbian, gay, and bisexual populations with respect to cancer, and inform about the types of programs and services needed to assist these cancer survivors.

    19. You have free access to this content
      Was race a factor in the outcomes of the women's health eating and living study? (pages 3805–3813)

      Raheem J. Paxton, Lovell A. Jones, Shine Chang, Mike Hernandez, Richard A. Hajek, Shirley W. Flatt, Loki Natarajan and John P. Pierce

      Article first published online: 11 FEB 2011 | DOI: 10.1002/cncr.25957

      The dietary intervention that was used in the Women's Healthy Eating and Living Study was associated with significant improvements in dietary patterns regardless of race/ethnicity. Despite improvements in overall dietary pattern, the intervention did not reduce the rates of second breast cancer events or improve overall survival in the diverse group of survivors.

    20. You have free access to this content
      Obesity is associated with breast cancer in African-American women but not Hispanic women in South Los Angeles (pages 3814–3823)

      Marianna Sarkissyan, Yanyuan Wu and Jaydutt V. Vadgama

      Article first published online: 8 FEB 2011 | DOI: 10.1002/cncr.25956

      The authors conducted a cross-sectional study of 471 African-American and Hispanic women with and without breast cancer in South Los Angeles. The data suggested an association between obesity and breast cancer, especially in postmenopausal women and most significantly in the African-American cohort.

    21. You have free access to this content
      Having health insurance does not eliminate race/ethnicity-associated delays in breast cancer diagnosis in the District of Columbia (pages 3824–3832)

      Heather J. Hoffman, Nancy L. LaVerda, Paul H. Levine, Heather A. Young, Lisa M. Alexander and Steven R. Patierno

      Article first published online: 24 FEB 2011 | DOI: 10.1002/cncr.25970

      Private health insurance increased the speed of diagnostic resolution in non-Hispanic blacks, but their delay remained significantly longer than the delay for privately insured non-Hispanic whites. Insured minorities waited more than twice as long to reach their diagnostic resolution than insured non-Hispanic whites, suggesting that diagnostic delays in minorities are more likely caused by other barriers associated with race/ethnicity than by health insurance status.

    22. Outcomes Research
      You have free access to this content
      Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada (pages 3833–3840)

      Isac S. F. Lima, Yutaka Yasui, Andrew Scarfe and Marcy Winget

      Article first published online: 11 FEB 2011 | DOI: 10.1002/cncr.25954

      Patients with stage III colon cancer who received adjuvant chemotherapy >12 weeks after surgery had a significantly increased risk of death compared with patients who received it within 12 weeks. The current results indicated that efforts are needed to improve the uptake and initiation of adjuvant chemotherapy within 12 weeks after surgery to maximize the survival of patients with stage III colon cancer.

    23. Epidemiology
      You have free access to this content
      Body mass index and risk of colorectal cancer in Chinese Singaporeans : The Singapore Chinese Health Study (pages 3841–3849)

      Andrew O. Odegaard, Woon Puay Koh, Mimi C. Yu and Jian Min Yuan

      Article first published online: 24 FEB 2011 | DOI: 10.1002/cncr.25936

      Prospective cohort data on the association between body mass index (BMI) and colorectal cancer in Asians is scarce as is data on underweight (BMI, <18.5 kg/m2) individuals in any population. BMI displays a U-shaped, quadratic association with colon cancer risk in this Chinese population in Southeast Asia.

    24. Psychosocial Oncology
      You have free access to this content
      Knowledge, attitudes, risk perception, and cancer screening behaviors among cancer survivors (pages 3850–3859)

      Dong Wook Shin, Young-Woo Kim, Jae Hwan Oh, Seok Won Kim, Ki-Wook Chung, Woo Yong Lee, Jeong Eon Lee, Won Chul Lee, Eliseo Guallar and Juhee Cho

      Article first published online: 11 FEB 2011 | DOI: 10.1002/cncr.25951

      Knowledge, attitudes, and risk perception in relation to second primary cancer screening are largely unknown. In the current study, cancer survivors were found to have limited knowledge regarding second cancer screening tests, which may have resulted in lower rates of completion of screening practices in this population.

    25. Symptom Control and Palliative Care
      You have free access to this content
      Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center (pages 3860–3866)

      Atul B. Shinagare, Mengye Guo, Hiroto Hatabu, Katherine M. Krajewski, Katherine Andriole, Annick D. Van den Abbeele, Pamela J. DiPiro and Mizuki Nishino

      Article first published online: 11 FEB 2011 | DOI: 10.1002/cncr.25941

      The incidence of pulmonary embolism in oncology outpatients in a tertiary cancer center over a 6-year period was 2.87%. Central nervous system, pancreatic, upper gastrointestinal, and lung/pleural malignancies had a significantly higher risk for pulmonary embolism than other malignancies, whereas hematologic and breast malignancies had a significantly lower risk.

  4. Erratum

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Erratum
    1. You have free access to this content
      Erratum (page 3867)

      Article first published online: 26 JAN 2011 | DOI: 10.1002/cncr.25966

      This article corrects:

      Clinical benefits of a multivariate prediction model for bladder cancer1

      Vol. 115, Issue 23, 5460–5469, Article first published online: 12 OCT 2009

SEARCH

SEARCH BY CITATION